Inventor · disambiguated record
Stanislas Blein
Also filed as: BLEIN STANISLAS
16 granted patents·19 pending applications·240 citations·filing 2009–2025
94Inventor score
Files withGLENMARK PHARMACEUTICALS SA17Ichnos Sciences SA10BLEIN STANISLAS3ATTINGER ANTOINE1BREWIS NEIL D1
Top patents by PatentIndex Score
35 records- 0196US9493563B2Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Nov 15, 2016·47 cites·3 claims
- 0294US11891454B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2020·Granted Feb 6, 2024·3 cites·15 claims
- 0394US9683053B2Hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Jun 20, 2017·38 cites·21 claims
- 0492US9683052B2Hetero-dimeric immunoglobulinsBLEIN STANISLAS·Filed 2012·Granted Jun 20, 2017·26 cites·10 claims
- 0592US9290576B2Antibodies that bind to TL1A and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Granted Mar 22, 2016·22 cites·51 claims
- 0692US8748585B2Antibodies that bind to OX40 and their usesATTINGER ANTOINE·Filed 2012·Granted Jun 10, 2014·36 cites·68 claims
- 0789US8679492B2Humanized antibodies that bind to CD19 and their usesBLEIN STANISLAS·Filed 2010·Granted Mar 25, 2014·35 cites·15 claims
- 0888US11851502B2Production of T cell retargeting hetero-dimeric immunoglobulinsIchnos Sciences SA·Filed 2018·Granted Dec 26, 2023·3 cites·13 claims
- 0985US8236315B2Humanized antibodies specific for von Willebrand factorLAZARIDES ELIAS·Filed 2009·Granted Aug 7, 2012·19 cites·126 claims
- 1082US11407839B2Antibodies that bind to OX40 and their usesIchnos Sciences SA·Filed 2019·Granted Aug 9, 2022·1 cites·30 claims
- 1182US8975376B2Anti-alpha2 integrin antibodies and their usesBLEIN STANISLAS·Filed 2011·Granted Mar 10, 2015·7 cites·14 claims
- 1281US12281169B2Antibodies that bind to OX40 and their usesIchnos Sciences SA·Filed 2022·Granted Apr 22, 2025·0 cites·28 claims
- 1377US2025250351A1Antibodies that bind to ox40 and their usesIchnos Sciences SA·Filed 2025·Application pending·0 cites
- 1465US9028822B2Antagonists against TNFR1 and methods of use thereforBREWIS NEIL D·Filed 2011·Granted May 12, 2015·3 cites·12 claims
- 1565US2020024367A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 1662US2014294824A1Antibodies that bind to ox40 and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 1761US2017145115A1Production of T cell retargeting hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 1859US2018094077A1Hetero-Dimeric ImmunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 1959US2020010568A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2058US12338292B2CD47-CD38 bispecific antibodiesIGI Therapeutics SA·Filed 2021·Granted Jun 24, 2025·0 cites·12 claims
- 2158US2017260280A1Antibodies that Bind to OX40 and Their UsesGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 2257US2020079863A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2019·Application pending·0 cites
- 2356US2024150489A1Cd47-cd38 bispecific antibodiesIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 2455US2024141062A1Cd47-cd38 bispecific antibodiesIchnos Sciences SA·Filed 2023·Application pending·0 cites
- 2554US2015183885A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 2652US2015239991A1Purification of hetero-dimeric immunoglobulinsGLENMARK PHARMACEUTICALS SA·Filed 2013·Application pending·0 cites
- 2751US2018086840A1Antibodies that bind to tl1a and their usesGLENMARK PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 2849US2013344064A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2013·Application pending·0 cites
- 2949US2016319027A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3047US2014286934A1Humanized antibodies that bind to cd19 and their usesGLENMARK PHARMACEUTICALS SA·Filed 2014·Application pending·0 cites
- 3146US11267891B2Fc variant antibodies and their usesSANOFI SA·Filed 2015·Granted Mar 8, 2022·0 cites·10 claims
- 3244US2017218087A1Anti-trka antibodies with enhanced inhibitory properties and derivatives thereofGLENMARK PHARMACEUTICALS SA·Filed 2016·Application pending·0 cites
- 3341US2020347143A1Novel tnfr agonists and uses thereofIchnos Sciences SA·Filed 2017·Application pending·0 cites
- 3438US10640564B2Antibodies that bind to CCR6 and their usesIchnos Sciences SA·Filed 2015·Granted May 5, 2020·0 cites·9 claims
- 3537US2023159661A1T cell redirecting bispecific antibodies for the treatment of egfr positive cancersIchnos Sciences SA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stanislas Blein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →